Ask AI
ProCE Banner Activity

EA1181/CompassHER2-pCR: Clinicopathologic Factors and Genomic Testing Associated With pCR After Adjuvant THP in Stage II-III HER2+ Breast Cancer

Conference Coverage
Slideset

In the single-arm phase II EA1181/CompassHER2-pCR, neoadjuvant treatment with THP was associated with improved pathologic complete response in patients with stage II and III HER2+ breast cancer and lower ER expression, weekly paclitaxel therapy, and higher HER2DX genomic test score.

Released: June 10, 2025

Expiration: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.